TFX Teleflex Incorporated

Teleflex Announces Quarterly Dividend

Teleflex Announces Quarterly Dividend

WAYNE, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable September 15, 2025, to shareholders of record at the close of business on August 15, 2025.

About Teleflex Incorporated

As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.

Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™ Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.

At Teleflex, we are empowering the future of healthcare. For more information, please visit .

Contacts:

Teleflex

Lawrence Keusch

Vice President, Investor Relations and Strategy Development



610-948-2836



EN
31/07/2025

Underlying

TFXTeleflex Incorporated

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Teleflex Incorporated

 PRESS RELEASE
Free
TFX Teleflex Incorp...

Teleflex Announces Quarterly Dividend

Teleflex Announces Quarterly Dividend WAYNE, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable September 15, 2025, to shareholders of record at the close of business on August 15, 2025. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthc...

July 31, 2025 1 EN
 PRESS RELEASE
Free
TFX Teleflex Incorp...

Teleflex Reports Second Quarter Financial Results and Full Year 2025 O...

Teleflex Reports Second Quarter Financial Results and Full Year 2025 Outlook WAYNE, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the second quarter ended June 29, 2025. Second quarter financial summary GAAP revenue of $780.9, up 4.2% compared to the prior year period; up 1.0% on an adjusted constant currency basis  GAAP diluted EPS from continuing operations of $2.77, compared to $1.69 in the prior year period Adjusted diluted EPS from continuing operations of $3.73, compared to $3.42 in the prior year...

July 31, 2025 1 EN
 PRESS RELEASE
Free
TFX Teleflex Incorp...

Teleflex Announces Second Quarter 2025 Earnings Conference Call Inform...

Teleflex Announces Second Quarter 2025 Earnings Conference Call Information WAYNE, Pa., July 17, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its second quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, July 31, 2025. To participate in the conference call, please utilize this to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company’s website, . An audio replay of the call will be available beginning at 11:00 am Easter...

July 17, 2025 1 EN
 PRESS RELEASE
Free
TFX Teleflex Incorp...

Teleflex Completes Acquisition of BIOTRONIK’s Vascular Intervention Bu...

Teleflex Completes Acquisition of BIOTRONIK’s Vascular Intervention Business WAYNE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced that it has completed the previously announced acquisition of substantially all of the Vascular Intervention business of BIOTRONIK SE & Co. KG. The acquisition adds a broad portfolio of therapeutic products to Teleflex’s portfolio of interventional access products, driving an enhanced global presence in the cath lab. The Vascular Intervention business will also establi...

July 1, 2025 1 EN
 PRESS RELEASE
Free
TFX Teleflex Incorp...

New Prospective Cohort Study Reporting the Efficacy of Arrow™ Chlorhex...

New Prospective Cohort Study Reporting the Efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters Demonstrates Reduced Infection Rates Among ICU Patients WAYNE, Pa., June 12, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced findings from a new multinational study reporting efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters (CVCs). This prospective cohort study included more than 6,670 patients from 12 Intensive care units in eight hospitals across India, Malaysia, Papua New Guin...

June 12, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch